Eli Lilly announced new data showing that Ebglyss (lebrikizumab-lbkz), a once-monthly biologic treatment for moderate-to-severe atopic dermatitis, achieved completely clear skin in 50% of patients and almost-clear skin in 87% of patients over three years. These findings come from the ADjoin long-term extension study and will be presented at the American Academy of Dermatology Annual Meeting.

Ebglyss is an interleukin-13 (IL-13) inhibitor that targets the primary cytokine involved in atopic dermatitis. The study included patients who initially responded to the treatment at Week 16 and continued with a maintenance dose of 250 mg every four weeks. More than 83% of these patients did not require additional topical corticosteroids or calcineurin inhibitors.

Additional studies showed significant improvements in itch, skin pain, and sleep loss due to itch, including in patients with skin of color and those previously treated with dupilumab. The safety profile remained consistent with prior clinical trials, with mild to moderate side effects such as conjunctivitis and injection-site reactions.

Ebglyss was approved in the U.S. in September 2024 as the first-line biologic treatment for moderate-to-severe atopic dermatitis in patients 12 years and older who do not respond to topical therapies. Lilly is working to expand insurance coverage through commercial, Medicaid, and Medicare plans to ensure broader patient access.